Blog - Bioverge

The Bioverge Podcast: Forging a TechBio Culture

Viswa Colluru, founder and CEO of Enveda Bio sits down with Neil to discuss AI in drug development, and the challenges of managing and forging a TechBio culture.

Investing

Impact Investing: Healthcare Startups vs The Stock Market

For retail investors, it has only become possible to invest in startups and private companies over the last 1-2 decades. This is largely the result of new legislation like Regulation CF and the proliferation of startup investing platforms. Prior to this, only well-connected investors with a significant net worth had the opportunity to invest in these companies.

Podcast

The Bioverge Podcast: Investing in the Bio-Based Future

Lindy Fishburne, managing partner of Breakout Ventures, sits down with Neil to discuss investing in seed- and early-stage bioscience companies, and what she learned working with entrepreneurial scientists at Breakout Labs.

Podcast

The Bioverge Podcast: Evolving Failures in an Evolving Pandemic and What Needs to Be Done

Dr. Eric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.

The Bioverge Podcast: Democratizing Entrepreneurship

Juan Scarlett, managing director of OneValley Ventures, sits down with Neil to discuss OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.

Investing, News & Media

The Evolving Landscape Of Funding And Investing In Biotech Startups

The investing world is rapidly evolving. Investors can now invest in private healthcare and biotech companies that were once the exclusive domain of professional investors.

Investing, News & Media

Healthcare-Focused Impact Investing: Another Way To Invest For Change

Healthcare provides another avenue in which investors can do well by doing good.

Health+Tech

Enveda is Harnessing the Power of Nature’s Chemistry

Bioverge recently invested in Enveda’s $51 million Series A led by Lux Capital. Enveda is biotechnology startup focused on harnessing the power of nature’s chemistry to develop next generation small-molecule therapeutics.

News & Media

Managed marketplaces and reality TV: How a new generation of gatekeepers is opening biotech up to amateur investors

"The average person will never get the chance to invest in a future unicorn like Moderna: The type of private equity deals that brought the now-famous biotech to the world are done in country clubs and coffee houses in a select few places, leaving anyone who is not a hedge fund manager, venture capitalist or disgustingly rich individual out of the game."

Podcast